Wang Wei, Liu Wen Bin, Huang Da Bing, Jia Wei, Ji Chu Shu, Hu Bing
Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University Hefei 230001, PR China.
Department of Hepatic Surgery, Anhui Provincial Hospital, Anhui Medical UniversityHefei 230001, PR China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary SurgeryHefei 230001, PR China.
Am J Cancer Res. 2016 Aug 1;6(8):1681-94. eCollection 2016.
Drug resistance is one of the main hurdles for the successful treatment of hepatic carcinoma. However, the detailed mechanisms underlying resistance remain largely unknown and therapeutic approaches are limited. In the present study, we show that miR-122 confers resistance to 5-fluorouracil induced hepatocellular carcinoma cell apoptosis in vitro and reduces the potency of 5-fluorouracil in the inhibition of tumor growth in a mouse xenograft model in vivo. Further studies indicate that miR-122 modulates drug resistance through down-regulation of expression of PCDH20, which belongs to the protocadherin gene family and negatively regulates Akt activation. Knockdown of PCDH20 expression increases Akt phosphorylation, which leads to elevated mTOR activity and enhanced 5-fluorouracil resistance; whereas rescue of PCDH20 expression in miR-122-expressing cells decreases Akt and mTOR phosphorylation, re-sensitizing hepatocellular carcinoma cell to 5-fluorouracil induced apoptosis. Moreover, a specific and potent Akt inhibitor reverses miR-122-conferred 5-fluorouracil resistance. These findings indicate that the miR-122/PCDH20/Akt/mTOR signaling axis has an important role in mediating response to chemotherapy in human hepatocellular carcinoma. A major implication of our study is that inhibition of miR-122 or restoration of PCDH20 expression may have significant therapeutic potential to overcome drug resistance in hepatocellular carcinoma and that the combined use of an Akt inhibitor with 5-fluorouracil may increase efficacy in liver cancer treatment.
耐药性是肝癌成功治疗的主要障碍之一。然而,耐药背后的详细机制仍 largely 未知,治疗方法也有限。在本研究中,我们表明 miR-122 在体外赋予对 5-氟尿嘧啶诱导的肝癌细胞凋亡的抗性,并在体内小鼠异种移植模型中降低 5-氟尿嘧啶抑制肿瘤生长的效力。进一步研究表明,miR-122 通过下调 PCDH20 的表达来调节耐药性,PCDH20 属于原钙黏蛋白基因家族,负向调节 Akt 激活。敲低 PCDH20 的表达会增加 Akt 磷酸化,导致 mTOR 活性升高和 5-氟尿嘧啶耐药性增强;而在表达 miR-122 的细胞中恢复 PCDH20 的表达会降低 Akt 和 mTOR 的磷酸化,使肝癌细胞对 5-氟尿嘧啶诱导的凋亡重新敏感。此外,一种特异性强效的 Akt 抑制剂可逆转 miR-122 赋予的 5-氟尿嘧啶耐药性。这些发现表明,miR-122/PCDH20/Akt/mTOR 信号轴在介导人类肝癌对化疗的反应中起重要作用。我们研究的一个主要意义是,抑制 miR-122 或恢复 PCDH20 的表达可能具有克服肝癌耐药性的显著治疗潜力,并且将 Akt 抑制剂与 5-氟尿嘧啶联合使用可能会提高肝癌治疗的疗效。